08/06/2021 8:43 AM
Clarín.com
Society
Updated 08/06/2021 9:26 AM
In the early hours of this Friday,
200,000 doses of the Convidecia vaccine
arrived at the Ezeiza international airport
, developed by the Chinese laboratory CanSino Biologics INC.
This is the first game of those contemplated in a contract for
5.4 million doses
, which should arrive in the remainder of this year.
Convidecia is, for now at least, a single-dose vaccine.
The Chinese pharmaceutical CanSino said weeks ago in a statement that it had decided to administer
a second dose
to the participants of a phase 3 trial, and thus "be in a position to study the possible benefits that a second booster dose could bring to the vaccine".
So it is possible that in the future it will be concluded that the vaccine works better with two applications.
At the same time, amid the controversy and questions about the delay in the arrival of component 2 of Sputnik V in the country, the Government evaluated at the time
combining the first doses of the Russian vaccine
with that of CanSino.
That was before it was decided to combine Sputnik with AstraZeneca and Modern.
Convidecia is one of the vaccines that was tested in Argentina.
Data from the Hospitable Foundation indicate that in February of this year,
8,000 volunteers participated in a phase III trial
of this formula.
The CanSino vaccine has the peculiarity that it can be kept for up to three months with
refrigeration between two and eight degrees Celsius
, so it does not require sophisticated equipment for transport and storage.
According to the first results applied, the vaccine achieved an effectiveness of 65.7% for symptomatic cases and
90.98% for severe cases
.
Authorized
This Chinese formula was
authorized for emergency use
against the coronavirus in June of this year.
The news was announced by the official Twitter account of the Ministry of Health of the Nation.
"The Minister of Health @carlavizzotti signed Resolution 2021-1671 that authorizes the emergency use of the CONVIDECIA vaccine from the company CanSino Biologics INC and advances the agreement for 5.4 million doses depending on their availability," said the health portfolio then .
The Ministry confirmed that the decision was made in accordance with the recommendations of the National Administration of Medicines, Food and Medical Technology (Anmat).
All vaccinations
As reported this Friday morning by the National Executive Power, since the beginning of the anticovid-19 campaign, Argentina received
42,801,930 doses of vaccines
, of which 14,768,000 correspond to Sinopharm;
11,868,830, to Sputnik V (9,375,670 of component 1 and 2,493,160 of component 2);
9,941,100, to those of AstraZeneca whose active principle was produced in Argentina;
3,500,000, to Moderna;
1,944,000 to AstraZeneca sent through the WHO Covax mechanism and 580,000 to AstraZeneca-Covishield.
And now, 200,000 from CanSino.
According to the Public Vaccination Monitor, 38,572,954 doses of vaccines were distributed throughout the territory as of this Friday morning, while
33,825,576 were applied
.
Of this total, 25,840,629 people were inoculated with the first dose and
7,984,947 have the complete
vaccination
scheme
.
News in development.
LGP
Look also
The Government approved the use of the Cansino laboratory vaccine and negotiates the purchase of 5.4 million doses
Coronavirus: the Government confirmed that the first doses of the Pfizer vaccine arrive in September